ReviewBritish journal of pharmacology2012
VPAC receptors: structure, molecular pharmacology and interaction with accessory proteins.
Review in British journal of pharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 118 citations in OpenAlex.
- Neuroplasticity and neuroimmune interactions with type 2 inflammation in asthma.European respiratory review : an official journal of the European Respiratory Society · 2026Review
- Amygdalin regulated vasoactive intestinal peptide receptor to protect alveolar epithelial barrier against lung injury induced by influenza a virus.Chinese medicine · 2025Article
- Acute REM sleep deprivation alleviated depression-like behavior mediated by inhibiting VIP neurons in the mPFC.Science advances · 2025Article
- VPAC1 and VPAC2 Receptor Heterozygosity Confers Distinct Biological Properties to BV2 Microglial Cells.Cells · 2025Article
- Emerging pharmacological targets for alcohol use disorder.Alcohol (Fayetteville, N.Y.) · 2024Review
- Arterial Hypertension: Novel Pharmacological Targets and Future Perspectives.Journal of clinical medicine · 2024Review
- Targeting genomic receptors in voided urine for confirmation of benign prostatic hyperplasia.BJUI compass · 2024Article
- 18Beta-Glycyrrhetinic Acid Attenuates HAntioxidants (Basel, Switzerland) · 2024Article
- Review
- Functional Expression of IP, 5-HTBiomolecules · 2023Article
- VPAC1 and VPAC2 receptor deficiencies negatively influence pregnancy outcome through distinct and overlapping modulations of immune, trophoblast and vascular functions.Biochimica et biophysica acta. Molecular basis of disease · 2023Article
- PACAP regulates VPAC1 expression, inflammatory processes and lipid homeostasis in M1- and M2-macrophages.Frontiers in cardiovascular medicine · 2023Article
- Vasoactive Intestinal Peptide (VIP) Protects Nile Tilapia (International journal of molecular sciences · 2022Article
- Article
- VIP plasma levels associate with survival in severe COVID-19 patients, correlating with protective effects in SARS-CoV-2-infected cells.Journal of leukocyte biology · 2022Article
- The Multifaceted Role of GPCRs in Amyotrophic Lateral Sclerosis: A New Therapeutic Perspective?International journal of molecular sciences · 2022Review
- New Insights on Metabolic and Genetic Basis of Migraine: Novel Impact on Management and Therapeutical Approach.International journal of molecular sciences · 2022Review
- Anticipated pharmacological role of Aviptadil on COVID-19.Environmental science and pollution research international · 2022Review
- G Protein-Coupled Receptors as Potential Intercellular Communication Mediators in Trypanosomatidae.Frontiers in cellular and infection microbiology · 2022Review
- Modulation of Prostanoids Profile and Counter-Regulation of SDF-1α/CXCR4 and VIP/VPAC2 Expression by Sitagliptin in Non-Diabetic Rat Model of Hepatic Ischemia-Reperfusion Injury.International journal of molecular sciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The vasoactive intestinal peptide (VIP) is a neuropeptide with wide distribution in both central and peripheral nervous systems, where it plays important regulatory role in many physiological processes. VIP displays a large biological functions including regulation of exocrine secretions, hormone release, fetal development, immune responses, etc. VIP appears to exert beneficial effect in neuro-degenerative and inflammatory diseases. The mechanism of action of VIP implicates two subtypes of receptors (VPAC1 and VPAC2), which are members of class B receptors belonging to the super-family of GPCR. This article reviews the current knowledge regarding the structure and molecular pharmacology of VPAC receptors. The structure-function relationship of VPAC1 receptor has been extensively studied, allowing to understand the molecular basis for receptor affinity, specificity, desensitization and coupling to adenylyl cyclase. Those studies have clearly demonstrated the crucial role of the N-terminal ectodomain (N-ted) of VPAC1 receptor in VIP recognition. By using different approaches including directed mutagenesis, photoaffinity labelling, NMR, molecular modelling and molecular dynamic simulation, it has been shown that the VIP molecule interacts with the N-ted of VPAC1 receptor, which is itself structured as a 'Sushi' domain. VPAC1 receptor also interacts with a few accessory proteins that play a role in cell signalling of receptors. Recent advances in the structural characterization of VPAC receptor and more generally of class B GPCRs will lead to the design of new molecules, which could have considerable interest for the treatment of inflammatory and neuro-degenerative diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.